Combination immunotherapy for advanced nasopharyngeal cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of three drugs—an immunotherapy (sintilimab), a targeted therapy (bevacizumab), and chemotherapy—for patients with high-risk, locally advanced nasopharyngeal cancer that has not spread to distant organs. The goal is to see if adding these drugs to standard chemoradiation improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be newly diagnosed with a specific type of nasopharyngeal cancer (non-keratinous, differentiated or undifferentiated).
- You must be between 18 and 75 years old.
- Your cancer should not have spread to distant organs (M0) but may have spread to lymph nodes in the neck.
- You should be in good general health (able to do daily activities, ECOG 0-1).
- You must not have had any other cancer in the last 3 years (except certain cured early-stage cancers).
- You must not have serious heart, lung, immune, or infectious conditions that would make the treatment unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an immunotherapy drug (which helps your immune system fight cancer) to standard chemotherapy can improve outcomes for people with advanced nasopharyngeal cancer (a type of cancer in the upper throat). If you qualify, you would receive this combination treatment as your first therapy for this stage of disease.
This trial tests a new immunotherapy drug (serplulimab) given together with standard chemotherapy and radiation for nasopharyngeal cancer that has spread to nearby lymph nodes. It aims to see if adding this drug can help shrink tumors and improve outcomes.
This trial tests a combination of three drugs as a first treatment for people with locally advanced nasopharyngeal cancer. It aims to see if the treatment shrinks tumors before standard therapy.
This trial tests a combination of three drugs (sintilimab, anlotinib, and chemotherapy) for nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this combination helps slow or shrink the cancer.
This trial tests two different chemotherapy combinations, each given with two extra drugs (one that targets cancer cells and one that boosts your immune system). It's for people with advanced nasopharyngeal cancer who haven't been treated yet, and it aims to see which combination works better.
This trial tests whether adding an immunotherapy drug called sintilimab to standard chemoradiotherapy (chemo and radiation) is better than chemoradiotherapy alone for a specific type of nasopharyngeal cancer that has spread to neck lymph nodes. Immunotherapy uses your own immune system to fight cancer, and the hope is that adding it before and after standard treatment can improve outcomes.
Hear when a new Locally Advanced Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.